TG-MV-005

Status: Completed

ClinicalTrials.gov Identifier: NCT00913744

TG-MV-005: Ocriplasmin injection in patients with wet AMD/focal vitreomacular adhesion.

Condition: 

  • Exudative Age-Related Macular Degeneration
  • Focal Vitreomacular Adhesion

Study Type: Interventional

Duration: 3 years & 2 months

Eligibility:

  • Ages: 50 years and older
  • Sexes: All
  • Accepts Healthy Volunteers: No

For more information on this study, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.